Related Experiment Videos
Ligand binding to CNS muscarinic receptor is transiently modified by convulsant 3-mercaptopropionic acid
P G Schneider1, G R de Lores Arnaiz
1Instituto de Biología Celular y Neurociencias Prof. Eduardo De Robertis, Facultad de Medicina, PROBICENE-CONICET, Universidad de Buenos Aires, Argentina.
Abstract:
The administration of convulsant drugs has proven a powerful tool to study experimental epilepsy. We have already reported that the administration of convulsant 3-mercaptopropionic acid (mp) at 150 mg/kg enhances binding affinity of muscarinic antagonist [3H]quinuclidinyl benzilate ([3H]QNB) to certain rat CNS membranes during seizure and postseizure without affecting site number. Results obtained with a 100-mg/kg dose of mp have shown reversible increases in [3H]QNB binding to cerebellum and hippocampus, whereas a delayed response has been found in striatum. Neither a subconvulsant dose nor in vitro addition modifies binding. In order to evaluate preseizure, seizure as well as early (30 min) and late (24 h) postseizure stages, we employed a 50 mg/kg dose and tested [3H]QNB binding to CNS membranes. Changes in binding were as follows (in %): in cerebellum, +37, +86, and +40 at preseizure, seizure and early postseizure stages, respectively, but there was a decrease at late postseizure; in hippocampus, +27 at pre- and seizure stages, but a decrease at early and late postseizure. No changes were found in striatum or cerebral cortex membranes at any stage studied. Saturation curves analysed by Scatchard plots indicated that changes in [3H]QNB binding to cerebellar membranes are attributable to an increase in ligand affinity at seizure, followed by a decrease in binding site number at postseizure. A similar profile was observed for hippocampus except that the decrease in binding site number, though lower than at postseizure, was already evident at seizure stage. Results confirm a region-specific response to the convulsant and transient changes provide an example of neuronal plasticity.
Insights
Convulsant drugs like 3-mercaptopropionic acid (mp) alter muscarinic antagonist binding in rat brains. These transient, region-specific changes demonstrate neuronal plasticity during experimental epilepsy.
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- Convulsant drugs are vital tools for studying experimental epilepsy.
- Previous research showed 3-mercaptopropionic acid (mp) enhances [3H]quinuclidinyl benzilate ([3H]QNB) binding during seizures.
- Dose-dependent effects of mp on [3H]QNB binding have been observed in specific brain regions.
Purpose of the Study:
- To investigate the impact of a 50 mg/kg dose of mp on [3H]QNB binding across different stages of induced seizures.
- To analyze changes in binding affinity and site number in various rat central nervous system (CNS) membranes.
- To explore region-specific alterations in muscarinic receptor binding during preseizure, seizure, and postseizure periods.
Main Methods:
- Administration of a 50 mg/kg dose of 3-mercaptopropionic acid (mp) to rats.
- Measurement of [3H]quinuclidinyl benzilate ([3H]QNB) binding to CNS membranes at preseizure, seizure, early postseizure (30 min), and late postseizure (24 h) stages.
- Analysis of binding data using Scatchard plots to determine changes in ligand affinity and binding site number.
Main Results:
- Significant increases in [3H]QNB binding were observed in the cerebellum and hippocampus during preseizure and seizure stages.
- Cerebellar membranes showed increased ligand affinity at seizure, followed by decreased binding site number postseizure.
- Hippocampal membranes exhibited decreased binding site number at seizure and postseizure stages, indicating region-specific responses.
Conclusions:
- The convulsant 3-mercaptopropionic acid induces region-specific, transient changes in muscarinic receptor binding in the rat CNS.
- Observed alterations in binding affinity and site number highlight the dynamic nature of neuronal plasticity in response to seizures.
- These findings contribute to understanding the neurobiological mechanisms underlying experimental epilepsy and neuronal adaptation.